Grifols SA (0RDU)

10.26
-0.23(-2.19%)
  • Volume:
    181,725
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    10.26 - 10.26

0RDU Overview

Prev. Close
10.49
Day's Range
10.26-10.26
Revenue
4.15B
Open
10.3
52 wk Range
7.83-20.28
EPS
0.088
Volume
181,725
Market Cap
6.36B
Dividend (Yield)
0.426
(2.27%)
Average Volume (3m)
280,451
P/E Ratio
106.42
Beta
0.136
1-Year Change
-41.9%
Shares Outstanding
678,910,694
Next Earnings Date
02 Mar 2023
What is your sentiment on Grifols?
or
Market is currently closed. Voting is open during market hours.

Grifols SA News

Grifols SA Company Profile

Grifols SA Company Profile

Employees
27584
Market
Spain

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Read More

Analyst Price Target

Average18.08 (+74.97% Upside)
High30
Low9
Price10.335
No. of Analysts17
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellNeutralBuyStrong Sell
Technical IndicatorsStrong SellStrong SellSellStrong BuyStrong Sell
SummaryStrong SellStrong SellNeutralStrong BuyStrong Sell
  • https://foro.trading/acciones-grifols/#posiciones-cortas
    0
    • Bearish
      0